158756-25-3

Basic information

• Product Name: 4-isothiocyanatobenzamide
• Synonyms: 4-isothiocyanatobenzamide
• CAS NO: 158756-25-3
• Molecular Formula: C₈H₆N₂OS
• Molecular Weight: 178.21104
• Mol File: 158756-25-3.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 370.6°C at 760 mmHg
• Flash Point: 177.9°C
• Appearance: /
• Density: 1.27g/cm³
• Vapor Pressure: 1.1E-05mmHg at 25°C
• Refractive Index: 1.631
• PKA: 15.52±0.50(Predicted)
• CAS DataBase Reference: 4-isothiocyanatobenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-isothiocyanatobenzamide(158756-25-3)
• EPA Substance Registry System: 4-isothiocyanatobenzamide(158756-25-3)

Safety Data

• Hazardous Substances Data: 158756-25-3(Hazardous Substances Data)

Usage

InChI:InChI=1/C8H6N2OS/c9-8(11)6-1-3-7(4-2-6)10-5-12/h1-4H,(H2,9,11)

Upstream product

• 463-71-8 thiophosgene 
• 2835-68-9 4-aminobenzamide 

Downstream Products

• 1239466-29-5 C₂₆H₂₀N₆OS 
• 1239466-21-7 C₂₆H₂₀N₆OS 
• 437750-61-3 4-(3-allylthioureido)benzamide 
• 1432790-53-8 C₁₆H₁₃N₅O₂S 
• 1338072-89-1 C₂₃H₁₈N₈OS 

Relevant articles and documents

Synthesis and biological evaluation of arylthiourea derivatives with antitubercular activity

Tuberculosis (TB) is a contagious disease caused by Mycobacterium tuberculosis (M. tuberculosis), and remains one of the most life-threatening plagues for public health in the world. The emergence of drug resistant strains of TB and co-infection with HIV has further complicated TB treatment. Here, the synthesis and characterizaton of a series of compounds were described, and these were followed by evaluating for their antibacterial activity against M. tuberculosis. Several novel arylthiourea derivatives exhibited excellent activity (lowest MIC=0.09 μg/ml) against M. tuberculosis including drug resistant strains of M. tuberculosis. The results suggest that these compounds are promising candidates for new anti-TB agent development.

Novel derivatives of benzimidazole and imidazo-pyridine and their use as medicaments

A compound of the formula wherein the substituents are as defined in the specification and pharmaceutical salts thereof having a good affinity for sub-types of melanocortin receptors making them useful for treating diseases in which such receptors are included such as pain, inflammatory conditions, etc.